Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.61 |
| ▸ | MAOB | P27338 | 6/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 7/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16622123 | 0.82 | HRH3 (0.49) | MAOAMAOBHRH3BRD4 | |
| SCHEMBL11099412 | 0.79 | ALDH1A1 (0.53) | MAOAMAOBHRH3BRD4 | |
| SCHEMBL10678387 | 0.79 | MAP2K1 (0.55) | MAOAMAOBHRH3PARP10PARP15 | |
| SCHEMBL10685054 | 0.79 | MAOA (0.54) | MAOAMAOBHRH3 | |
| SCHEMBL7649580 | 0.78 | MAOA (0.56) | MAOAMAOBHRH3PARP10PARP15 | |
| SCHEMBL1034102 | 0.78 | HSD17B1 (0.51) | MAOAMAOBHRH3PARP10PARP15 | |
| SCHEMBL10606492 | 0.77 | HRH3 (0.63) | MAOAMAOBHRH3BRD4 | |
| SCHEMBL1033318 | 0.77 | MAOA (0.46) | MAOAMAOBPARP10PARP15BRD4 | |
| SCHEMBL15818207 | 0.77 | MAOB (0.60) | MAOAMAOB | |
| SCHEMBL6391911 | 0.76 | BRD4 (0.64) | MAOAMAOBHRH3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| EP-3176172-A1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | Astrazeneca AB (SE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2655378-B1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-03-01 | — | — | EP | disclosed |
| US-9000185-B2 | Cycloalkyl ether compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2015-04-07 | — | — | US | disclosed |
| US-8865911-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2014-10-21 | — | — | US | disclosed |
| US-8865911-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2014-10-21 | — | — | US | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | ASTRAZENECA INTELLECTUAL PROPERTY | 2013-08-15 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415483-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165347-A1 | Compounds and their use as BACE Inhibitors | BACE1, BACE2, APP | MAOA 136/4885MAOB 75/4885HRH3 2646/4885 |
| US-20130210837-A1 | Compounds and Their Use as BACE Inhibitors | BACE1, BACE2, APP | MAOA 136/4885MAOB 75/4885HRH3 2646/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | MAOA 136/4885MAOB 75/4885HRH3 2646/4885 |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | MAOA 136/4885MAOB 75/4885HRH3 2646/4885 |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | MAOA 136/4885MAOB 75/4885HRH3 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.